Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gynecologic Oncology

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2016.01.026PMID 26827964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficient molecular subtype classification of high‐grade serous ovarian cancer

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015influential reference
• POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.

  2014cited by this paper
• Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.

  2014cited by this paper
• Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

  2014cited by this paper
• Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.

  2013cited by this paper
• Synthetic lethality between CCNE1 amplification and loss of BRCA1

  2013cited by this paper
• Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

  2013cited by this paper
• A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy

  2012cited by this paper
• Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

  2012cited by this paper
• Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.

  2012cited by this paper
• Whole Transcriptome RNA-Seq Analysis of Breast Cancer Recurrence Risk Using Formalin-Fixed Paraffin-Embedded Tumor Tissue

  2012cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012cited by this paper
• High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

  2012cited by this paper
• Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer

  2012cited by this paper
• Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.

  2012cited by this paper
• IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

  2011cited by this paper
• A seven-gene prognostic model for platinum-treated ovarian carcinomas

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets

  2010cited by this paper
• Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

  2010influential reference
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• The basics of epithelial-mesenchymal transition.

  2009cited by this paper
• A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

  2009cited by this paper
• Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer

  2009cited by this paper
• Gene Expression Profiles as Prognostic Markers in Women With Ovarian Cancer

  2009cited by this paper
• A prognostic gene expression index in ovarian cancer—validation across different independent data sets

  2009cited by this paper
• Biomarkers for epithelial-mesenchymal transitions.

  2009cited by this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cited by this paper
• Clinical application of the 70-gene profile: the MINDACT trial.

  2008cited by this paper
• A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

  2008cited by this paper
• Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

  2008cited by this paper
• Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

  2007cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.

  2006cited by this paper
• Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

  2005cited by this paper
• Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon

  2005cited by this paper
• Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

  2005cited by this paper
• Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy

  2005cited by this paper
• Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

  2005cited by this paper
• Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers

  2005cited by this paper
• Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

  2005cited by this paper
• Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion

  2005cited by this paper
• Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2

  2004cited by this paper
• Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

  2004cited by this paper
• The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use

  2004cited by this paper
• Gene expression patterns in ovarian carcinomas.

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Cancer statistics

  1989cited by this paper

• Integrative prognostic modeling of ovarian cancer: incorporating genetic, clinical, and immunological markers

  2025cites this paper
• The Progression and Prospects of the Gene Expression Profiling in Ovarian Epithelial Cancer

  2024cites this paper
• Integrated analysis of single-cell and bulk transcriptome reveals hypoxia-induced immunosuppressive microenvironment to predict immunotherapy response in high-grade serous ovarian cancer

  2024cites this paper
• Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.

  2024cites this paper
• Ovarian Cancer: A Landscape of Mitochondria with Emphasis on Mitochondrial Dynamics

  2023cites this paper
• Ovarian cancer‐specific dysregulated genes with prognostic significance: scRNA‐Seq with bulk RNA‐Seq data and experimental validation

  2022cites this paper
• cAMP-Dependent Signaling and Ovarian Cancer

  2022cites this paper
• Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition

  2022cites this paper
• CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

  2021cites this paper
• Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer

  2021cites this paper
• Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer

  2021cites this paper
• Identification of Significant Genes in Lung Cancer of Nonsmoking Women via Bioinformatics Analysis

  2021cites this paper
• Personalized Models of Heterogenous 3D Epithelial Tumor Microenvironments: Ovarian Cancer as a Model.

  2021cites this paper
• IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

  2020cites this paper
• Mechanistically derived patient-level framework for precision medicine identifies a personalized immune prognostic signature in high-grade serous ovarian cancer

  2020cites this paper
• Chemoresistance-associated alternative splicing signatures in serous ovarian cancer.

  2020cites this paper
• Genomic profiling of platinum-resistant ovarian cancer: the road into druggable targets.

  2020cites this paper
• Biological Insights into Chemotherapy Resistance in Ovarian Cancer

  2019cites this paper
• Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.

  2019cites this paper
• Radiomics: an Introductory Guide to What It May Foretell

  2019cites this paper
• Ovarian cancer: An update on imaging in the era of radiomics.

  2019cites this paper
• An Ensemble Strategy to Predict Prognosis in Ovarian Cancer Based on Gene Modules

  2019cites this paper
• Radiomique : mode d’emploi. Méthodologie et exemples d’application en imagerie de la femme

  2019cites this paper
• Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis

  2018cites this paper
• Identification of prognostic signature in cancer based on DNA methylation interaction network

  2017cites this paper
• A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis.

  2017cites this paper
• A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells

  2017cites this paper
• Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation

  2017cites this paper
• Identifying prognostic signature in ovarian cancer using DirGenerank

  2017cites this paper